These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 16962155)

  • 1. Matrix protein of VSV New Jersey serotype containing methionine to arginine substitutions at positions 48 and 51 allows near-normal host cell gene expression.
    Kim GN; Kang CY
    Virology; 2007 Jan; 357(1):41-53. PubMed ID: 16962155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of vesicular stomatitis virus M protein mutants in cell rounding is correlated with the ability to inhibit host gene expression and is not correlated with virus assembly function.
    Lyles DS; McKenzie MO
    Virology; 1997 Mar; 229(1):77-89. PubMed ID: 9123880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a consensus mutation in M protein of vesicular stomatitis virus from persistently infected cells that affects inhibition of host-directed gene expression.
    Ahmed M; Lyles DS
    Virology; 1997 Oct; 237(2):378-88. PubMed ID: 9356348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity.
    Hoffmann M; Wu YJ; Gerber M; Berger-Rentsch M; Heimrich B; Schwemmle M; Zimmer G
    J Gen Virol; 2010 Nov; 91(Pt 11):2782-93. PubMed ID: 20631091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assembly functions of vesicular stomatitis virus matrix protein are not disrupted by mutations at major sites of phosphorylation.
    Kaptur PE; McKenzie MO; Wertz GW; Lyles DS
    Virology; 1995 Feb; 206(2):894-903. PubMed ID: 7856102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency of wild-type and temperature-sensitive vesicular stomatitis virus matrix protein in the inhibition of host-directed gene expression.
    Lyles DS; McKenzie MO; Ahmed M; Woolwine SC
    Virology; 1996 Nov; 225(1):172-80. PubMed ID: 8918544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of serotype specificity in transcription of vesicular stomatitis virus synthetic nucleocapsids.
    Smallwood S; Richards-Sumners E; Moyer SA
    Virology; 1994 Feb; 199(1):11-9. PubMed ID: 8116233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors.
    Kim GN; Wu K; Hong JP; Awamleh Z; Kang CY
    J Virol; 2015 Jun; 89(12):6338-51. PubMed ID: 25855732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
    Ahmed M; Cramer SD; Lyles DS
    Virology; 2004 Dec; 330(1):34-49. PubMed ID: 15527832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host.
    Martinez I; Barrera JC; Rodriguez LL; Wertz GW
    Vaccine; 2004 Sep; 22(29-30):4035-43. PubMed ID: 15364454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal replication of vesicular stomatitis virus without C proteins.
    Kretzschmar E; Peluso R; Schnell MJ; Whitt MA; Rose JK
    Virology; 1996 Feb; 216(2):309-16. PubMed ID: 8607260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-layered membrane vesicles released from mammalian cells infected with Sendai virus expressing the matrix protein of vesicular stomatitis virus.
    Sakaguchi T; Uchiyama T; Fujii Y; Kiyotani K; Kato A; Nagai Y; Kawai A; Yoshida T
    Virology; 1999 Oct; 263(1):230-43. PubMed ID: 10544097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
    J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.
    Ebert O; Harbaran S; Shinozaki K; Woo SL
    Cancer Gene Ther; 2005 Apr; 12(4):350-8. PubMed ID: 15565179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression.
    An HY; Kim GN; Wu K; Kang CY
    Virus Res; 2013 Jan; 171(1):168-77. PubMed ID: 23207069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix protein mutations contribute to inefficient induction of apoptosis leading to persistent infection of human neural cells by vesicular stomatitis virus.
    Desforges M; Despars G; Bérard S; Gosselin M; McKenzie MO; Lyles DS; Talbot PJ; Poliquin L
    Virology; 2002 Mar; 295(1):63-73. PubMed ID: 12033766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a new region in the vesicular stomatitis virus L polymerase protein which is essential for mRNA cap methylation.
    Grdzelishvili VZ; Smallwood S; Tower D; Hall RL; Hunt DM; Moyer SA
    Virology; 2006 Jul; 350(2):394-405. PubMed ID: 16537083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common distribution of antigenic determinants and complementation activity on matrix proteins of two vesicular stomatitis virus serotypes.
    Sun W; Huang L; Wagner RR
    J Gen Virol; 1994 Apr; 75 ( Pt 4)():937-43. PubMed ID: 7512123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic amino acid residues at the carboxy-terminal eleven amino acid region of the phosphoprotein (P) are required for transcription but not for replication of vesicular stomatitis virus genome RNA.
    Das T; Pattnaik AK; Takacs AM; Li T; Hwang LN; Banerjee AK
    Virology; 1997 Nov; 238(1):103-14. PubMed ID: 9375014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity to mount protective antibody responses against pathogen infections.
    Senn BM; López-Macías C; Kalinke U; Lamarre A; Isibasi A; Zinkernagel RM; Hengartner H
    Eur J Immunol; 2003 Apr; 33(4):950-61. PubMed ID: 12672061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.